Cervical Squamous Intraepithelial Neoplasia 2 clinical trials at UC Cancer
1 research study open to eligible people
open to eligible females ages 21 years and up
This phase II trial studies the effect of pembrolizumab on cervical intraepithelial neoplasia. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Our lead scientists for Cervical Squamous Intraepithelial Neoplasia 2 medical studies include John A Glaspy, MD.